Anti-tuberculosis drugs and human polymorphonuclear leukocyte functions

Area of Science:

• Immunology
• Pharmacology
• Infectious Diseases

Background:

• Polymorphonuclear leukocytes (PMNs) play a crucial role in early human tuberculosis (TB) immune responses.
• The standard DOTS (directly observed treatment, short-course) strategy for TB employs four key drugs: rifampicin, isoniazid, pyrazinamide, and ethambutol.

Purpose of the Study:

• To investigate the effects of individual and combined anti-TB drugs on human PMN functions.
• To determine if anti-TB medications influence PMN phagocytosis and oxidative burst capacity.

Main Methods:

• Human PMNs were exposed to subtherapeutic, therapeutic, and supratherapeutic concentrations of the four primary anti-TB drugs.
• Phagocytosis and oxidative burst assays were performed using Staphylococcus aureus as a stimulus.
• Flow cytometry was utilized to quantify PMN functional responses.

Main Results:

• No significant impact on PMN phagocytosis was observed across all drug concentrations tested.
• A notable attenuation in oxidative burst capacity occurred only at supratherapeutic concentrations of isoniazid and the combined drug regimen.
• Lower drug concentrations did not demonstrate significant effects on oxidative burst.

Conclusions:

• The study suggests that observed PMN functional impairments in TB patients are likely attributable to the disease process itself.
• Anti-TB drug treatment, at standard and even elevated concentrations, does not appear to be the primary cause of PMN dysfunction in TB.